
Techcyte
Founded Year
2013Stage
Series C | AliveTotal Raised
$34.62MLast Raised
$8.4M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-40 points in the past 30 days
About Techcyte
Techcyte focuses on aiding in the practice of pathology with its artificial intelligence (AI) software platform in the clinical pathology sector. It offers a range of AI-assisted diagnostic tools that improve the efficiency and accuracy of laboratory testing. Techcyte's solutions cater to various applications, including oncology, microbiology, hematology, and infectious disease, as well as industries such as veterinary, environmental, and human healthcare. It was founded in 2013 and is based in Orem, Utah.
Loading...
ESPs containing Techcyte
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…
Techcyte named as Leader among 15 other companies, including Proscia, Ibex, and PathAI.
Loading...
Research containing Techcyte
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Techcyte in 3 CB Insights research briefs, most recently on Jul 15, 2024.


Aug 10, 2023
The oncology tech market mapExpert Collections containing Techcyte
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Techcyte is included in 3 Expert Collections, including Digital Health.
Digital Health
11,255 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
456 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence
7,212 items
Techcyte Patents
Techcyte has filed 10 patents.
The 3 most popular patent topics include:
- hematology
- immunologic tests
- microscopy

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/17/2020 | 5/28/2024 | Microscopy, Microscopes, Lens mounts, Cell imaging, Staining | Grant |
Application Date | 1/17/2020 |
---|---|
Grant Date | 5/28/2024 |
Title | |
Related Topics | Microscopy, Microscopes, Lens mounts, Cell imaging, Staining |
Status | Grant |
Latest Techcyte News
Nov 8, 2024
News Provided By Share This Article Our ISO 17025 accreditation underscores our dedication to providing the highest level of service and reliability to our customers, validating our commitment to excellence in laboratory testing.” — Jason Callahan OREM, UT, UNITED STATES, November 8, 2024 / EINPresswire.com / -- Sporecyte, the industry leader in AI-powered digital mold and particulate analysis, is proud to announce its achievement of ISO/IEC 17025:2017 accreditation from Perry Johnson Laboratory Accreditation (PJLA), further reinforcing its dedication to technical excellence, precision, and consistent reliability in environmental testing. This prestigious lab accreditation demonstrates Sporecyte’s commitment to upholding the highest standards of accuracy, competence, and integrity, ensuring the most dependable results for its customers. ISO/IEC 17025:2017 is an internationally recognized standard for testing and calibration laboratories, confirming that Sporecyte meets rigorous global benchmarks for both technical competence and laboratory management. This accomplishment underscores Sporecyte’s ongoing drive to refine its operational processes and deliver industry-leading mold testing services, powered by cutting-edge AI technology. "Our ISO 17025 accreditation underscores our dedication to providing the highest level of service and reliability to our customers," said Jason Callahan, General Manager at Sporecyte. "It validates our commitment to excellence in laboratory testing and ensures that our AI-driven reports are produced with the utmost precision and adherence to international standards." The benefits of this certification extend beyond Sporecyte, setting a benchmark for other companies in the industry and encouraging broader adoption of sustainable and responsible practices. Customers can have full confidence that Sporecyte’s AI-driven mold testing services are not only accurate and efficient but also delivered with a commitment to environmental responsibility. By earning ISO 17025 lab accreditation, Sporecyte not only enhances its reputation for superior quality and innovation but also solidifies its role as a leader in sustainability within the mold testing industry. Through the strategic use of technology to streamline processes and reduce environmental impact, Sporecyte continues to set the standard in responsible, AI-powered diagnostics. About Sporecyte: Sporecyte has developed the world’s first AI-powered mold and air particulate report. We focus on providing home inspectors and industry professionals access to fast, accurate, and affordable mold and air quality testing. About Techcyte: Founded in 2013 in Orem, Utah, Techcyte is a world leader in AI-based digital diagnostics, including clinical and anatomic pathology. Techcyte’s AI and workflow platform uses AI to perform analysis of whole slide images, transforming diagnostics for human, animal, and environmental labs around the world. Visit techcyte.com for more information. Ben Cahoon
Techcyte Frequently Asked Questions (FAQ)
When was Techcyte founded?
Techcyte was founded in 2013.
Where is Techcyte's headquarters?
Techcyte's headquarters is located at 1106 North 1200 West, Orem.
What is Techcyte's latest funding round?
Techcyte's latest funding round is Series C.
How much did Techcyte raise?
Techcyte raised a total of $34.62M.
Who are the investors of Techcyte?
Investors of Techcyte include Alta Ventures Mexico, Zoetis, ARUP Laboratories, Paycheck Protection Program, University of Utah and 3 more.
Loading...
Loading...